Effective treatment of a child with adenoidal hypertrophy and severe asthma by omalizumab: a case report.

"Declarations Ethics approval and consent to participateParticipant and his parents received a statement on ethics and gave written consent. This study was approved by the Biomedical Research Ethical Committee of Peking University First Hospital, approval number 2021 − 250. Consent for publicationParticipant consent included a consent for publication. Competing interestsAll the authors have no example conflicts of interest to disclose and this manuscript has not been published elsewhere and is not under consideration by another journal. All authors have approved the manuscript and agree with this submission. Competing interests All the authors have no example conflicts of interest to disclose and this manuscript has not been published elsewhere and is not under consideration by another journal. All authors have approved the manuscript and agree with this submission."

"Funding All phases of this study were supported by the National Natural Science Foundation of China (NSFC) (No. 81971424 to L.Y.). The NSFC had no role in the design and conduct of the study."